

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

ENZO BIOCHEM INC  
Form 10-Q  
June 11, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-Q

Mark one

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2007

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-09974

ENZO BIOCHEM, INC.

-----  
(Exact name of registrant as specified in its charter)

|   |                                       |
|---|---------------------------------------|
| New York  | 13-2866202                            |
| -----   | -----                                 |
| (State or Other Jurisdiction<br>of Incorporation or Organization) | (IRS. Employer<br>Identification No.) |
| 527 Madison Ave, New York, New York                               | 10022                                 |
| -----   | -----                                 |
| (Address of Principal Executive office)                           | (Zip Code)                            |

212-583-0100  
-----  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

|                                |   |
|--------------------------------|---|
| Common Stock, \$0.01 par value | New York Stock Exchange                     |
| -----                          | -----                                       |
| (Title of Class)               | (Name of Each Exchange on which Registered) |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐

Indicate by check mark whether the registrant is a shell company (as defined in

# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

Rule 12b-2 of the Exchange Act.)

Yes [ ] No [X]

As of June 1, 2007, the Registrant had approximately 36,704,000 shares of Common Stock outstanding.

ENZO BIOCHEM, INC.  
FORM 10-Q  
April 30, 2007

## INDEX

### PART I - FINANCIAL INFORMATION

|         |  |    |
|---------|--|----|
| Item 1. | Consolidated Financial Statements  |    |
|         | Consolidated Balance Sheets  |    |
|         | April 30, 2007 (unaudited) and July 31, 2006   | 3  |
|         | Consolidated Statements of Operations  |    |
|         | For the three and nine months ended April 30, 2007 and 2006 (unaudited)                  | 4  |
|         | Consolidated Statements of Cash Flows  |    |
|         | For the nine months ended April 30, 2007 and 2006 (unaudited)                            | 5  |
|         | Notes to Consolidated Financial Statements   | 6  |
| Item 2. | Management's Discussion and Analysis of<br>Financial Condition and Results of Operations | 17 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk                               | 30 |
| Item 4. | Controls and Procedures  | 30 |

### PART II - OTHER INFORMATION

|          |                   |    |
|----------|-------------------|----|
| Item 1.  | Legal Proceedings | 31 |
| Item 1A. | Risk Factors      | 31 |
| Item 6.  | Exhibits          | 31 |
|          | Signatures        | 31 |

# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

## ENZO BIOCHEM, INC. CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT SHARE DATA)

| ASSETS  | April 30,<br>2007<br>(unaudited)<br>----- |
|---|---|
| Current assets:   |   |
| Cash and cash equivalents   | \$120,024                                 |
| Accounts receivable, net of allowances  | 11,779                                    |
| Other receivables   | 1,500                                     |
| Inventories   | 2,121                                     |
| Prepaid expenses  | 739                                       |
| Recoverable and prepaid income taxes  | 1,765                                     |
|   | -----                                     |
| Total current assets  | 137,928                                   |
| Property, plant, and equipment, net of accumulated<br>depreciation and amortization   | 6,181                                     |
| Goodwill  | 7,452                                     |
| Patent costs, net of accumulated amortization   | 1,198                                     |
| Other   | 1,699                                     |
|   | -----                                     |
| Total assets  | \$154,458<br>=====                        |
| LIABILITIES AND STOCKHOLDERS' EQUITY  |   |
| Current liabilities:  |   |
| Accounts payable - trade  | \$1,595                                   |
| Accrued liabilities   | 6,233                                     |
| Other current liabilities   | 1,024                                     |
|   | -----                                     |
| Total current liabilities   | 8,852                                     |
| Deferred revenue  | 1,050                                     |
| Commitments and contingencies   |   |
| Stockholders' equity:   |   |
| Preferred Stock, \$.01 par value; authorized 25,000,000 shares; no<br>shares issued or outstanding  | -   |
| Common Stock, \$.01 par value; authorized 75,000,000 shares; shares<br>issued: 37,298,500 at April 30, 2007 and 32,844,200 at July 31, 2006 | 373                                       |
| Additional paid-in capital  | 295,272                                   |
| Less treasury stock at cost: 596,500 shares at April 30, 2007<br>and 569,700 shares at July 31, 2006  | (8,915)                                   |
| Accumulated deficit   | (142,174)                                 |
|   | -----                                     |
| Total stockholders' equity  | 144,556<br>-----                          |
| Total liabilities and stockholders' equity  | \$154,458<br>=====                        |

# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

3

The accompanying notes are an integral part of these consolidated financial statements

## ENZO BIOCHEM, INC. CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED (IN THOUSANDS, EXCEPT PER SHARE DATA)

|   | Three Months Ended<br>April 30, |           | Nin       |
|---|---------------------------------|-----------|-----------|
|   | 2007                            | 2006      | 2007      |
|   | ----                            | ----      | ----      |
| Revenues:                                       |                                 |           |           |
| Product revenues                                | \$883                           | \$1,179   | \$2,699   |
| Royalty income                                  | 1,547                           | 717       | 3,756     |
| Clinical laboratory services                    | 11,530                          | 7,734     | 28,543    |
|   | -----                           | -----     | -----     |
|   | 13,960                          | 9,630     | 34,998    |
| Costs and expenses and other (income):          |                                 |           |           |
| Cost of product revenues                        | 773                             | 588       | 1,698     |
| Cost of clinical laboratory services            | 5,253                           | 3,384     | 12,815    |
| Research and development expense                | 2,614                           | 1,901     | 6,935     |
| Selling, general, and administrative expense    | 6,235                           | 6,153     | 19,015    |
| Provision for uncollectible accounts receivable | 1,338                           | 517       | 3,433     |
| Legal expense                                   | 3,049                           | 1,719     | 7,159     |
| Interest income                                 | (1,548)                         | (839)     | (3,627)   |
| Other income                                    | -                               | -         | (2,699)   |
|   | -----                           | -----     | -----     |
|   | 17,714                          | 13,423    | 44,729    |
|   | -----                           | -----     | -----     |
| Loss before income taxes                        | (3,754)                         | (3,793)   | (9,731)   |
| (Provision) benefit for income taxes            | (79)                            | 357       | (199)     |
|   | -----                           | -----     | -----     |
| Net loss  | (\$3,833)                       | (\$3,436) | (\$9,930) |
|   | =====                           | =====     | =====     |
| Net loss per common share:                      |                                 |           |           |
| Basic   | (\$0.10)                        | (\$0.11)  | (\$0.29)  |
|   | =====                           | =====     | =====     |
| Diluted   | (\$0.10)                        | (\$0.11)  | (\$0.29)  |
|   | =====                           | =====     | =====     |
| Weighted average common shares outstanding:     |                                 |           |           |
| Basic   | 36,630                          | 32,245    | 34,46     |
|   | =====                           | =====     | =====     |
| Diluted   | 36,630                          | 32,245    | 34,46     |
|   | =====                           | =====     | =====     |

4

# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The accompanying notes are an integral part of these consolidated financial statements

## ENZO BIOCHEM, INC CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED (IN THOUSANDS)

|   | Nine Months<br>April<br>2007 |
|---|------------------------------|
| OPERATING ACTIVITIES  |                              |
| Net loss  | (\$9,930)                    |
| Adjustments to reconcile net loss to net cash used in operating activities: |                              |
| Depreciation and amortization of property, plant and equipment              | 736                          |
| Amortization of patent costs  | 59                           |
| Provision for uncollectible accounts receivable                             | 3,433                        |
| Write-off and/or reserve for obsolete inventory                             | 365                          |
| Deferred taxes  | -                            |
| Share based compensation charges  | 1,182                        |
| Issuance of stock for 401(k) employer match                                 | 419                          |
| Loss on marketable securities   | -                            |
| Other   | 8                            |
| Changes in operating assets and liabilities:                                |                              |
| Accounts receivable   | (4,765)                      |
| Other receivables   | (1,500)                      |
| Inventories   | (85)                         |
| Prepaid expenses  | 726                          |
| Recoverable and prepaid income taxes  | 166                          |
| Accounts payable - trade  | 291                          |
| Accrued liabilities   | 1,098                        |
| Other current liabilities   | 794                          |
| Long term deferred revenue  | 1,050                        |
| Adjustments   | 3,977                        |
| Net cash used in operating activities                                       | (5,953)                      |
| INVESTING ACTIVITIES  |                              |
| Capital expenditures  | (1,069)                      |
| Sales of marketable securities  | -                            |
| Purchases of marketable securities  | -                            |
| Increase in cash surrender values   | (88)                         |
| Increase in security deposits   | (10)                         |
| Net cash (used in) provided by investing activities                         | (1,167)                      |
| FINANCING ACTIVITIES  |                              |
| Net proceeds from issuance of common stock                                  | 56,997                       |
| Proceeds from the exercise of stock options                                 | 293                          |

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

|  |           |
|--|-----------|
| Net cash provided by financing activities            | 57,290    |
| Net increase (decrease) in cash and cash equivalents | 50,170    |
| Cash and cash equivalents at the beginning of period | 69,854    |
| Cash and cash equivalents at the end of period       | \$120,024 |

5

The accompanying notes are an integral part of  
these consolidated financial statements

### ENZO BIOCHEM, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of April 30, 2007  
and for the three and nine month periods ended  
April 30, 2007 and 2006  
(Unaudited)

#### NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly owned subsidiaries, Enzo Clinical Labs, Enzo Life Sciences, Enzo Therapeutics and Enzo Realty LLC (the "Company" or "Companies"). The consolidated balance sheet as of April 30, 2007 and the consolidated statements of operations and statements of cash flows for the three and nine month periods ended April 30, 2007 and 2006 are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2006 and notes thereto contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2006 has been derived from the audited financial statements at that date. The results of operations for the three and nine months ended April 30, 2007 are not necessarily indicative of the results to be expected for the entire fiscal year ending July 31, 2007.

#### Recent Accounting Pronouncements

In May 2005, the FASB issued SFAS No. 154, "Accounting Changes and Error Corrections ("SFAS 154"), a replacement of APB Opinion No. 20, Accounting Changes, and FASB Statement No. 3, Reporting Accounting Changes in Interim Financial Statements". SFAS 154 changes the requirements for the accounting for and reporting of a change in accounting principle. Previously, most voluntary changes in accounting principles required recognition via a cumulative effect adjustment within net income for the period of the change. SFAS 154 requires retrospective application to prior periods' financial statements, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS 154 is effective for accounting changes made in fiscal years beginning after December 15, 2005; however, SFAS 154 does not change the transition provisions of any existing accounting pronouncements. The adoption of SFAS 154 did not have a material impact on the Company's financial

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

condition or results of operations.

In June 2006, the FASB issued FASB Interpretation No. 48 ("FIN 48"), "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, Accounting for Income Taxes" ("SFAS 109"), to clarify the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with SFAS 109. This Interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. The Company has not evaluated the impact of FIN 48 on its financial statements at this time.

6

In September 2006, the SEC released Staff Accounting Bulletin No. 108 "Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements" ("SAB 108"). SAB 108 provides interpretative guidance on how public companies quantify financial statement misstatements. There have been two common approaches used to quantify such errors. Under an income statement approach, the "roll-over" method, the error is quantified as the amount by which the current year income statement is misstated. Alternatively, under a balance sheet approach, the "iron curtain" method, the error is quantified as the cumulative amount by which the current year balance sheet is misstated. In SAB 108, the SEC established an approach that requires quantification of financial statement misstatements based on the effects of the misstatements on each of the company's financial statements and the related financial statement disclosures. This model is commonly referred to as a "dual approach" because it requires quantification of errors under both the roll-over and iron curtain methods. SAB 108 is effective for the Company as of August 1, 2007. The adoption of SAB 108 is not expected to have a material impact on the Company's consolidated financial statements.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". This Statement defines fair value, establishes a framework for measuring fair value and expands disclosure about fair value measurements, and is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company has not evaluated the effect that the adoption of this Statement will have on its financial statements at this time.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an amendment of FASB Statement No. 115" ("SFAS 159"). This statement permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS 159 is effective as of the beginning of fiscal years that begin after November 15, 2007. The Company has not evaluated the effect that the adoption of this Statement will have on its financial statements at this time.

### Reclassifications

Certain balances in the prior period have been reclassified to conform to the presentation in the current period.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

### NOTE 2 - NET LOSS PER SHARE

Basic net loss per common share is computed using the weighted average number of common shares outstanding during the three and nine months ended April 30, 2007 and 2006. Diluted net loss per common shares is computed using the weighted average number of shares outstanding during the three and nine months ended April 30, 2007 and 2006, and excludes the effect of dilutive potential common shares (consisting of employee stock options and unvested restricted stock awards) as their inclusion would be antidilutive. Accordingly, basic and diluted net loss per share is the same during these periods.

7

The following table summarizes the potential number of shares issued from exercise of "in the money" stock options, net of shares repurchased with the option exercise proceeds, and potential shares from restricted stock awards, which are excluded from the computation of diluted net loss per share.

| (In thousands)   | Three months ended<br>April 30, |            | Nine months ended<br>April 30, |            |
|--|---------------------------------|------------|--------------------------------|------------|
|  | 2007                            | 2006       | 2007                           | 2006       |
|  | ----                            | ----       | ----                           | ----       |
| Potential net shares, issued from exercise of "in the money" employee and director stock options and restricted stock awards, excluded from diluted net loss per share calculation | 733<br>===                      | 408<br>=== | 621<br>===                     | 451<br>=== |

The following table summarizes the number of "out of the money" options excluded from the computation of diluted net loss per share because the effect of their potential exercise is anti-dilutive.

| (In thousands)                   | Three months ended<br>April 30, |                | Nine months ended<br>April 30, |                |
|----------------------------------|---------------------------------|----------------|--------------------------------|----------------|
|                                  | 2007                            | 2006           | 2007                           | 2006           |
|                                  | ----                            | ----           | ----                           | ----           |
| "Out of the money" stock options | 905<br>===                      | 1,109<br>===== | 905<br>===                     | 1,109<br>===== |

### NOTE 3 - SHARE-BASED COMPENSATION

The Company adopted SFAS No. 123(R), "Share-Based Payment" ("SFAS 123(R)") and related interpretations effective August 1, 2005. Compensation costs recognized in the three and nine month periods ended April 30, 2007 and 2006 include compensation costs for all share-based payments granted prior to, but not yet vested as of July 31, 2005, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, and compensation costs for all share-based payments granted subsequent to August 1, 2005, based on the grant fair value estimated in accordance with the provisions of SFAS 123(R).



## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The following table sets forth the amount of share-based compensation expense upon vesting and per share data related to share-based payment arrangements included in the accompanying statements of operations:

| In thousands, except per share data<br>-----             | Three months ended<br>April 30, |        | Nine months ended<br>April 30, |         |
|--|---------------------------------|--------|--------------------------------|---------|
|  | 2007                            | 2006   | 2007                           | 2006    |
| -----  | -----                           | -----  | -----                          | -----   |
| Stock options  | \$91                            | \$427  | \$767                          | \$1,182 |
| Restricted stock awards                                  | 221                             | 57     | 415                            | 1,182   |
|  | -----                           | -----  | -----                          | -----   |
| Total  | \$312                           | \$484  | \$1,182                        | \$1,182 |
|  | =====                           | =====  | =====                          | =====   |
| Impact on basic and diluted net loss per<br>common share | \$0.01                          | \$0.01 | \$0.03                         | \$0.03  |
|  | =====                           | =====  | =====                          | =====   |
| As included in the statements of operations<br>-----     |                                 |        |                                |         |
| Cost of product revenues                                 | \$4                             | \$ --  | \$10                           | \$10    |
| Research and development                                 | 50                              | 38     | 148                            | 148     |
| Selling, general and administrative                      | 258                             | 446    | 1,024                          | 1,024   |
|  | -----                           | -----  | -----                          | -----   |
|  | \$312                           | \$484  | \$1,182                        | \$1,182 |
|  | =====                           | =====  | =====                          | =====   |

No excess tax benefits were recognized during the three and nine month periods ended April 30, 2007 and 2006.

8

### STOCK OPTION PLANS

A summary of the activity relating to the Company's stock option plans for the nine month period ended April 30, 2007 is as follows:

|                                       | Options   | Weighted Average<br>Exercise Price | Agg<br>Intrinsic |
|---------------------------------------|-----------|------------------------------------|------------------|
|                                       | -----     | -----                              | -----            |
| Outstanding at August 1, 2006         | 2,877,727 | \$13.20                            | \$3,727,727      |
| Granted                               | -         | -                                  | -                |
| Exercised                             | (71,696)  | \$9.88                             | (71,696)         |
| Cancelled                             | (75,447)  | \$13.12                            | (75,447)         |
|                                       | -----     |                                    |                  |
| Outstanding at end of period          | 2,730,584 | \$13.29                            | \$11,584,584     |
|                                       | =====     |                                    | =====            |
| Exercisable at end of period          | 2,552,637 | \$13.34                            | \$10,863,637     |
|                                       | =====     |                                    | =====            |
| Available for grant at April 30, 2007 | 607,300   |                                    |                  |

# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

=====

The Company did not grant stock options during the nine months ended April 30, 2007. As of April 30, 2007, there was approximately \$495,000 of total unrecognized compensation cost related to nonvested stock option-based compensation, which will be recognized over a weighted average life of approximately one year.

During the nine months ended April 30, 2007 and 2006, the Company received cash proceeds of approximately \$293,000 and \$363,000, respectively, from the exercise of 28,584 and 34,191 stock options, respectively. The aggregate intrinsic value of stock options exercised during the nine months ended April 30, 2007 and 2006, including the non-cash transactions (Note 4) was approximately \$0.4 million and \$0.6 million, respectively.

During the year ended July 31, 2006, the Company granted 100,000 options to a consultant with an exercise price of \$24.84, which vested over nine months and have a two year term. The fair value of these options on September 6, 2006 (the vesting date) was \$89,000. The fair value of the options, which was accounted for as a variable instrument, was fair valued and recognized as expense over the nine month vesting term. The assumptions used to fair value this option grant were as follows: risk free interest rate of 4.97%, expected term of 2 years, expected volatility of 49%, and no dividend yield. In connection with the options issued to this consultant, the Company recognized an expense of approximately \$8,000 in selling, general and administrative expense in the accompanying statement of operations for the nine months ended April 30, 2007.

## RESTRICTED STOCK AWARDS

During the nine months ended April 30, 2007, the compensation committee of the Company's board of directors approved grants of restricted stock-based compensation awards (the "Awards") of 72,400 shares to certain independent directors, executive officers and employees. During the nine months ended April 30, 2006, the compensation committee of the Company's board of directors approved Awards of 67,950 shares, inclusive of cancellations of 7,500 shares.

A summary of the activity pursuant to the Company's Awards for the nine months ended April 30, 2007 is as follows:

|                             | Awards   | Weighted Average<br>Award Price |
|-----------------------------|----------|---------------------------------|
|                             | -----    | -----                           |
| Nonvested at August 1, 2006 | 77,450   | \$12.21                         |
| Granted                     | 72,400   | \$14.85                         |
| Vested                      | (18,663) | \$13.39                         |
| Cancelled                   | (6,800)  | \$13.41                         |
|                             | -----    |                                 |
| Nonvested at end of period  | 124,387  | \$13.30                         |
|                             | =====    |                                 |

The fair value of nonvested shares is determined based on the closing stock price on the grant date. As of April 30, 2007, there was approximately \$1.3 million of total unrecognized compensation cost related to nonvested restricted stock-based compensation to be recognized over a weighted average period of two years.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

Supplemental information with respect to the Company's consolidated statements of cash flows is as follows:

| (In thousands)   | Nine months ended April 30, |      |
|------------------|-----------------------------|------|
|                  | 2007                        | 2006 |
|                  | ----                        | ---- |
| Taxes paid - net | \$26                        | \$2  |
|                  | ====                        | ==== |

During the nine months ended April 30, 2007, certain officers of the Company exercised 43,112 stock options in a non-cash transaction. The officers surrendered 26,697 shares of previously acquired common stock to exercise the stock options. The Company recorded approximately \$0.4 million, the market value of the surrendered shares, as treasury stock.

During the nine months ended April 30, 2006, certain officers of the Company exercised 221,116 stock options in a non-cash transaction. The officers surrendered 180,411 shares of previously acquired common stock to exercise the stock options. The Company recorded approximately \$2.4 million, the market value of the surrendered shares, as treasury stock.

### NOTE 5 - INVENTORIES

Inventories, net of reserves for excess and obsolete inventory of \$360,000 and \$238,000, respectively, consist of the following, as of:

| (In thousands)    | April 30, 2007 | July 31, 2006 |
|-------------------|----------------|---------------|
| -----             | -----          | -----         |
| Raw materials     | \$15           | \$38          |
| Work in process   | 1,102          | 1,518         |
| Finished products | 1,004          | 845           |
|                   | -----          | -----         |
|                   | \$2,121        | \$2,401       |
|                   | =====          | =====         |

### NOTE 6 - ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES

Accrued liabilities consist of:

| In 000'S                           | April 30, 2007 | July 31, 2006 |
|------------------------------------|----------------|---------------|
| -----                              | -----          | -----         |
| Legal                              | \$2,905        | \$1,974       |
| Payroll, benefits, and commissions | 1,227          | 868           |
| Research and development           | 469            | 408           |
| Professional fees                  | 907            | 369           |
| Outside reference lab testing      | 50             | 122           |
| Other                              | 675            | 662           |
|                                    | -----          | -----         |
|                                    | \$6,233        | \$4,403       |
|                                    | =====          | =====         |

Other current liabilities consist of:

| In 000'S            | April 30, 2007 | JULY 31, 2006 |
|---------------------|----------------|---------------|
| -----               | -----          | -----         |
| Installment payable | \$ -           | \$150         |

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

|                  |         |       |
|------------------|---------|-------|
| Deferred revenue | 770     | 80    |
| Other            | 254     | -     |
|                  | -----   | ----- |
|                  | \$1,024 | \$230 |
|                  | =====   | ===== |

### NOTE 7 - INCOME TAXES

At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.

The tax provisions for the three and nine months ended April 30, 2007 were based on state and local taxes, and differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency.

The tax benefit for the three months ended April 30, 2006 differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to limitations on the timing of the recognition of the Company's then available federal tax carryback benefit for taxes paid in prior years. The tax benefit also differs from the expected net operating loss carryforward benefit due to the inability to recognize such benefit. The carryforward benefit could not be recognized because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency.

The tax benefit for the nine months ended April 30, 2006 differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to limitations on the timing of the recognition of the Company's then available federal tax carryback benefit for taxes paid in prior years. The tax benefit also differs from the expected net operating loss carryforward benefit due to the inability to recognize such benefit. The carryforward benefit could not be recognized because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency.

Also due to these uncertainties, the Company recorded during the first quarter of the 2006 period a valuation allowance equal to its net deferred tax assets, including the federal net operating loss carryforward benefit generated during the first quarter of the 2006 period. The Company recorded the valuation allowance as it concluded that it was not more likely than not that its net deferred tax assets would be realized in the foreseeable future based on positive and negative evidence available at the time.

In November 2005, the FASB issued FSP FAS 123(R)-3, "Transition Election Related to Accounting for the Tax Effects of Share-Based Payment Awards", to provide an alternate transition method for the implementation of SFAS 123(R). Because some entities do not have, and may not be able to re-create, information about the net excess tax benefits that would have qualified as such had those entities adopted SFAS 123(R) for recognition purposes, this FSP provides an elective alternative transition method. The method comprises (a) a computational component that establishes a beginning balance of the additional paid in capital pool ("APIC pool") related to employee compensation and (b) a simplified method to determine the subsequent impact on the APIC pool of employee awards that are fully vested and outstanding upon the adoption of SFAS 123(R). The Company

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

adopted the principles set forth in this FSP to determine its APIC pool.

### NOTE 8 - ROYALTY INCOME

In fiscal 2005, the Company as plaintiff finalized and executed a settlement and license agreement with Digene Corporation to settle a patent litigation lawsuit (the "Agreement"). Subsequent to the settlement, the Agreement provides for the Company to receive quarterly running royalties on the net sales of Digene products subject to the license until the expiration of the patent in April 2018. Royalty income arising from the Agreement is included in the Life Sciences segment (see Note 12).

### NOTE 9 - OTHER INCOME

#### GAIN ON PATENT LITIGATION SETTLEMENT

The Company as plaintiff and Sigma Aldrich ("Sigma") entered into a Settlement Agreement and Release effective September 15, 2006 (the "Settlement Agreement"). Pursuant to the Settlement Agreement, the Company's litigation with Sigma was dismissed and the Company recognized a \$2 million gain on patent litigation settlement included in "Other income" in the accompanying consolidated statement of operations for the nine months ended April 30, 2007.

#### PAYMENT FROM FORMER DISTRIBUTOR

During the quarter ended January 31, 2007, the Company received a payment of approximately \$699,000 from Perkin Elmer Inc. ("Perkin Elmer") for amounts due under a Distribution Agreement (the "Distribution Agreement") which terminated December 31, 2004. The Distribution Agreement is presently subject to a lawsuit for breach of contract, patent infringement, unfair competition under state law, unfair competition under federal law, tortious interference with business relations, and fraud in the inducement of contract. Perkin Elmer advised in a letter to the Company that the payment was owed under the Distribution Agreement and was delayed because of changes to their accounting system and personnel changes and that it was always their intent to comply with the Distribution Agreement. The Company advised Perkin Elmer that the payment did not represent all amounts owed under the Distribution Agreement. Accordingly, the payment has been included in "Other income" in the accompanying consolidated statements of operations for the nine months ended April 30, 2007.

12

### NOTE 10 - LICENSING AND SUPPLY AGREEMENT:

On April 26, 2007 (the "Effective Date") Enzo Life Sciences, Inc. ("Life Sciences") and Abbott Molecular Inc. ("Abbott") entered into an agreement covering the supply of certain of Life Science's products to Abbott for use in their product line. The supply arrangement has a term of 5 years. The parties have also entered into a limited non-exclusive royalty bearing cross-licensing agreement ("Licensing Agreement") for various patents. The Licensing Agreement requires each party to pay royalties, as defined through the lives of the related covered patents. In connection with a component of the License Agreement, Abbott will pay a one-time fee of \$1.5 million, relating to a fully paid-up license and sublicense, as defined. The one-time fee will be deferred and recognized as revenue over the expected patents' lives. At April 30, 2007, the Company's consolidated balance sheet includes a receivable for the aforementioned \$1.5 million and corresponding deferred revenue. No recognition of the aforementioned deferred revenue occurred through April 30, 2007. During the quarter ended April 30, 2007, Life Sciences recorded \$575,000 in royalties

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

under the component of the Licensing Agreement that provided for royalty payments effective from September 1, 2006.

The Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, "Revenue Recognition" (SAB 104), when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed and determinable, and (iv) collectibility is reasonably assured. The Company evaluates revenue from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting as defined in EITF Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables" (EITF 00-21). To recognize revenue for a delivered item in a multiple element arrangement, EITF 00-21 requires that the delivered items have value to the customer on a stand-alone basis, there is objective and reliable evidence of fair value of the undelivered items, and delivery of any undelivered items is probable and within our control.

### NOTE 11 - STOCKHOLDERS' EQUITY

On December 8, 2006, the Securities and Exchange Commission ("SEC") declared effective the shelf Registration Statement the Company filed on Form S-3 on November 13, 2006. The shelf Registration Statement allows the Company to offer and sell up to an aggregate of \$100 million of common stock from time to time in one or more offerings. The terms of any such offering would be established at the time of such offering.

On December 14, 2006, the Company entered into a Placement Agent Agreement with Lazard Capital Markets LLC, as exclusive placement agent, relating to a "registered direct" offering ("Offering") of shares of the Company's common stock. On December 15, 2006, the Company entered into a definitive Subscription Agreement with various institutional investors relating to the sale of an aggregate of 3,285,715 shares of common stock for a purchase price of \$14.00 per share. Net proceeds from the Offering aggregating \$42.9 million, net of placement fees and financing costs of \$3.1 million, were credited to common stock and additional paid-in capital. On December 15, 2006, the Company filed a prospectus supplement with the SEC relating to the Offering under the Registration Statement and supplement thereto.

13

On February 2, 2007, the Company entered into a Placement Agent Agreement with Lazard Capital Markets LLC, as exclusive placement agent, relating to a "registered direct" offering ("Subsequent Offering") of shares of the Company's common stock. On February 2, 2007, the Company entered into a definitive Subscription Agreement with an investor relating to the sale of an aggregate of 1,000,000 shares of common stock for a purchase price of \$15.00 per share. Net proceeds from the Subsequent Offering aggregated \$14.1 million, net of placement fees and financing costs of \$0.9 million were credited to common stock and additional paid in capital. On February 5, 2007, the Company filed a prospectus supplement with the SEC relating to the Subsequent Offering under the Registration Statement and supplement thereto.

### NOTE 12 - SEGMENT REPORTING

The Company has three reportable segments: Life Sciences, Therapeutics, and Clinical Labs. The Company's Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company's Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Clinical Labs segment provides diagnostic services to the medical community. Prior to the fourth quarter ended July 31, 2006, the Life

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

Sciences and Therapeutics segments were reported together as the Research and Development segment. The April 30, 2006 segment information has been restated to reflect this change. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as other consist of corporate general and administrative costs which are not allocable to the three reportable segments. Certain expenses were reclassified among segments in the fiscal 2006 periods for comparative purposes.

Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of critical accounting policies.

14

The following financial information (in thousands) represents the operating results of the reportable segments of the Company:

THREE MONTHS ENDED APRIL 30, 2007

| REVENUES:  | Life Sciences<br>----- | Therapeutics<br>----- | Clinical<br>----- |
|--|------------------------|-----------------------|-------------------|
| Product revenues                                 | \$883                  | --                    |                   |
| Royalty income                                   | 1,547                  | --                    |                   |
| Clinical laboratory services                     | --                     | --                    | \$                |
|  | --                     | --                    | -                 |
|  | 2,430                  | --                    |                   |
| <br>COST AND EXPENSES AND OTHER (INCOME):        |                        |                       |                   |
| Cost of products                                 | 773                    | --                    |                   |
| Cost of clinical laboratory services             | --                     | --                    |                   |
| Research and development                         | 749                    | \$1,865               |                   |
| Provision for uncollectible accounts             | --                     | --                    |                   |
| Selling, general and administrative and legal    | 471                    | --                    |                   |
| Interest income                                  | --                     | --                    |                   |
| Other income                                     | --                     | --                    |                   |
|  | --                     | --                    |                   |
| <br>Income (loss) before income taxes            | \$437<br>=====         | (\$1,865)<br>=====    |                   |
| <br>Depreciation and amortization included above | \$43<br>===            | \$4<br>==             |                   |
| <br>SHARE-BASED COMPENSATION INCLUDED IN ABOVE:  |                        |                       |                   |
| Cost of products                                 | \$4                    | --                    |                   |
| Research and development                         | 17                     | \$33                  |                   |
| Selling, general and administrative and legal    | 8                      | --                    |                   |
|  | -                      | --                    |                   |
| Total  | \$29<br>=====          | \$33<br>=====         |                   |
| <br>Capital expenditures                         | \$365<br>=====         | \$9<br>==             |                   |

# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

THREE MONTHS ENDED APRIL 30, 2006

| REVENUES:  | Life Sciences | Therapeutics | Clinical |
|--|---------------|--------------|----------|
|  | -----         | -----        | -----    |
| Product revenues                                 | \$1,179       | --           |          |
| Royalty income                                   | 717           | --           |          |
| Clinical laboratory services                     | --            | --           |          |
|  | --            | --           |          |
|  | 1,896         | --           |          |
| <br>COST AND EXPENSES AND OTHER (INCOME):        |               |              |          |
| Cost of products                                 | 588           | --           |          |
| Cost of clinical laboratory services             | --            | --           |          |
| Research and development                         | 880           | \$1,021      |          |
| Provision for uncollectible accounts             | --            | --           |          |
| Selling, general and administrative and legal    | 631           | --           |          |
| Interest income                                  | --            | --           |          |
|  | --            | --           |          |
| <br>Income (loss) before income taxes            | (\$203)       | (\$1,021)    |          |
|  | =====         | =====        |          |
| <br>Depreciation and amortization included above | \$44          | \$2          |          |
|  | ===           | ==           |          |
| <br>SHARE-BASED COMPENSATION INCLUDED IN ABOVE:  |               |              |          |
| Cost of products                                 | --            | --           |          |
| Research and development                         | \$2           | \$36         |          |
| Selling, general and administrative and legal    | 33            | --           |          |
|  | --            | --           |          |
| Total  | \$35          | \$36         |          |
|  | ===           | ===          |          |
| <br>Capital expenditures                         | \$20          | \$ -         |          |
|  | ===           | ===          |          |

15

NINE MONTHS ENDED APRIL 30, 2007

| REVENUES:                                 | Life Sciences | Therapeutics | Clinical |
|---|---------------|--------------|----------|
|   | -----         | -----        | -----    |
| Product revenues                          | \$2,699       | --           |          |
| Royalty income                            | 3,756         | --           |          |
| Clinical laboratory services              | --            | --           | \$       |
|   | --            | --           | --       |
|   | 6,455         | --           |          |
| <br>COST AND EXPENSES AND OTHER (INCOME): |               |              |          |
| Cost of products                          | 1,698         | --           |          |
| Cost of clinical laboratory services      | --            | --           |          |



# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

|   |         |           |
|---|---------|-----------|
| Research and development                      | 2,481   | \$4,454   |
| Provision for uncollectible accounts          | --      | --        |
| Selling, general and administrative and legal | 1,479   | --        |
| Interest income                               | --      | --        |
| Other income                                  | (2,699) | --        |
|   | -----   | --        |
| Income (loss) before income taxes             | \$3,496 | (\$4,454) |
|   | =====   | =====     |
| Depreciation and amortization included above  | \$135   | \$11      |
|   | =====   | =====     |
| SHARE-BASED COMPENSATION INCLUDED IN ABOVE:   |         |           |
| Cost of products                              | \$10    | --        |
| Research and development                      | 53      | \$95      |
| Selling, general and administrative and legal | 23      | --        |
|   | --      | --        |
| Total   | \$86    | \$95      |
|   | =====   | =====     |
| Capital expenditures                          | \$426   | \$16      |
|   | =====   | =====     |

NINE MONTHS ENDED APRIL 30, 2006

| REVENUES:                                     | Life Sciences | Therapeutics | Clinical |
|---|---------------|--------------|----------|
|   | -----         | -----        | -----    |
| Product revenues                              | \$3,900       | --           |          |
| Royalty income                                | 2,251         | --           |          |
| Clinical laboratory services                  | --            | --           | \$       |
|   | --            | --           | --       |
|   | 6,151         | --           |          |
| COST AND EXPENSES AND OTHER (INCOME):         |               |              |          |
| Cost of products                              | 1,515         | --           |          |
| Cost of clinical laboratory services          | --            | --           |          |
| Research and development                      | 2,659         | \$2,702      |          |
| Provision for uncollectible accounts          | --            | --           |          |
| Selling, general and administrative and legal | 1,724         | --           |          |
| Interest income                               | --            | --           |          |
|   | --            | --           |          |
| Income (loss) before income taxes             | \$253         | (\$2,702)    |          |
|   | =====         | =====        |          |
| Depreciation and amortization included above  | \$135         | \$8          |          |
|   | =====         | =====        |          |
| SHARE-BASED COMPENSATION INCLUDED IN ABOVE:   |               |              |          |
| Cost of products                              | \$18          | --           |          |
| Research and development                      | 92            | \$108        |          |
| Selling, general and administrative and legal | 73            | --           |          |
|   | --            | --           |          |
| Total   | \$183         | \$108        |          |
|   | =====         | =====        |          |
| Capital expenditures                          | \$32          | \$ -         |          |

## NOTE 13- SUBSEQUENT EVENT

Effective May 31, 2007 (the "Effective Date"), the Company's wholly owned subsidiary, Enzo Life Sciences, Inc., completed the acquisition of the stock of Axxora Life Sciences, Inc., ("Axxora") a privately owned global manufacturer and marketer of life sciences research products, for approximately \$16.3 million in cash. On the Effective Date, Axxora became a wholly owned subsidiary of Enzo Life Sciences. Axxora had revenues of approximately \$16 million in 2006. Axxora has wholly-owned subsidiaries in the U.S., Switzerland, Germany and the United Kingdom, as well as distributors located in other major markets. At April 30, 2007, the Company has recorded approximately \$732,000 in acquisition costs which are included in "Other assets" in the accompanying balance sheet.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. See "Forward-Looking and Cautionary Statements" in our Form 10-K for the year ended July 31, 2006. Because of those factors, you should not rely on past financial results as an indication of future performance. We believe that period-to-period comparisons of our financial results to date are not necessarily meaningful and expect that our results of operations might fluctuate from period to period in the future.

The Company is a life sciences and biotechnology company focused on harnessing genetic processes to develop research tools and therapeutics and the provision of diagnostic services to the medical community. Since its founding in 1976, the Company's strategic focus has been on the development, for commercial purposes, of enabling technologies in the life sciences field. The Company's pioneering work in genomic analysis coupled with its extensive patent estate and enabling platforms have strategically positioned the Company to play a crucially important role in the rapidly growing life sciences and molecular medicine marketplaces.

The Company is comprised of three interconnected operating companies that have evolved out of the Company's core competence: the use of nucleic acids as informational molecules and the use of compounds for immune response modulation. These wholly owned operating Companies conduct their operations through three segments (see Note 12 in the notes to consolidated financial statements).

The Company's sources of revenue from the Life Sciences segment is from the direct sales of products consisting of labeling and detection reagents for the genomics and sequencing markets, as well as through non-exclusive distribution agreements with other companies and royalty income. The Company's other source of revenue is from the clinical laboratory service market. Payments for clinical laboratory testing services are made by the Medicare program, healthcare insurers and patients. Fees billed to patients, Medicare, and third party providers are billed on the laboratory's standard gross fee schedule, subject to any limitations on fees negotiated with the third party providers or with the ordering physicians on behalf of their patients.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The Company incurs additional costs as a result of our participation in the Medicare programs, as billing and reimbursement for clinical laboratory testing is subject to considerable and complex federal regulations. Compliance with applicable laws and regulations, as well as internal compliance policies and procedures, adds further complexity and costs to our operations.

17

Government providers such as Medicare, as well as healthcare insurers have taken steps and may continue to take steps to control the costs, utilizations and delivery of healthcare services, including clinical laboratory services. Despite the added cost and complexity of participating in the Medicare program, we continue to participate because we believe that our other lab services business from ordering physicians may depend, in part, on continued participation in Medicare since certain ordering physicians may want a single laboratory capable of performing all of their clinical laboratory testing services, regardless of who pays for such services.

Information systems are used extensively in virtually all aspects of the clinical laboratory operations, including testing, billing, customer service, logistics, and management of medical data. Our success depends, in part, on the continued and uninterrupted performance of our information technology systems. Through maintenance, staffing, and investments in our information technology system, we expect to limit the risk associated with our heavy reliance on these systems.

The clinical laboratory is subject to seasonal fluctuations in operating results and cash flows. Typically, testing volume declines during the summer months, year end holiday periods and other major holidays, reducing net revenues and operating cash flows. Testing volume is also subject to declines in winter months due to inclement weather, which varies in severity from year to year.

For the three months ended April 30, 2007 and 2006, approximately 6% and 12% of the Company's operating revenues were derived from product sales and approximately 11% and 8% were derived from royalty income, respectively, and approximately 83% and 80% were derived from clinical laboratory services, respectively. For the nine months ended April 30, 2007 and 2006, approximately 8% and 13% of the Company's operating revenues were derived from product sales and approximately 11% and 8% were derived from royalty income, respectively, and approximately 81% and 79% were derived from clinical laboratory services, respectively.

### COMPARATIVE OPERATING DATA

| (in 000's)                                 | Three months ended<br>April 30, |         | Increase<br>(Decrease) |
|--|---------------------------------|---------|------------------------|
| REVENUES:                                  | 2007                            | 2006    | -----                  |
|  | ----                            | ----    |                        |
| Product revenues                           | \$883                           | \$1,179 | \$ (296)               |
| Royalty income                             | 1,547                           | 717     | 830                    |
| Clinical laboratory services               | 11,530                          | 7,734   | 3,796                  |
|  | -----                           | -----   | -----                  |
| Total revenues                             | 13,960                          | 9,630   | 4,330                  |
| <br>COSTS AND EXPENSES AND OTHER (INCOME): |                                 |         |                        |
| Cost of products                           | 773                             | 588     | 185                    |

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

|                                     |           |           |       |
|-------------------------------------|-----------|-----------|-------|
| Cost of laboratory services         | 5,253     | 3,384     | 1,869 |
| Research & development              | 2,614     | 1,901     | 713   |
| Selling, general and administrative | 6,235     | 6,153     | 82    |
| Provision for uncollectible A/R     | 1,338     | 517       | 821   |
| Legal expenses                      | 3,049     | 1,719     | 1,330 |
| Interest income                     | (1,548)   | (839)     | (709) |
| Other income                        | -         | -         | -     |
|                                     | ---       | ---       | ----  |
| Total costs and expenses - net      | 17,714    | 13,423    | 4,291 |
|                                     | -----     | -----     | ----- |
| Loss before income taxes            | (\$3,754) | (\$3,793) | \$39  |
|                                     | =====     | =====     | ===   |

18

### RESULTS OF OPERATIONS

THREE MONTHS ENDED APRIL 30, 2007 AS COMPARED TO APRIL 30, 2006

#### CONSOLIDATED RESULTS

Product revenues during the three months ended April 30, 2007 were \$0.9 million compared to \$1.2 million in the year ago quarter, a decrease of \$0.3 million or 25% due to a decline in unit shipments and the continuing competitiveness in the industry.

Royalty income during the three months ended April 30, 2007 was \$1.5 million compared to \$0.7 million in the year ago quarter, an increase of \$0.8 million or 116%. Royalties are earned from net sales of Digene products subject to a license and royalties earned from Abbott under a License Agreement entered into in the Fiscal 2007 quarter. There are no expenses relating to royalty income.

Clinical laboratory revenues during the three month period ended April 30, 2007 was \$11.5 million compared to \$7.7 million in the year ago quarter, an increase of \$3.8 million or 49%. The Company experienced an increase in service revenues during the 2007 period due to an expansion of an insurance provider agreement, partially offset by an increase in the contractual adjustment expense which reduced gross billings by 79.8% as compared to 75.4% in the year ago period. The increase in the contractual adjustment expense is due to continued competitive pricing throughout the industry.

The cost of products during the three month period ended April 30, 2007 was \$0.8 million compared to \$0.6 million in the year ago quarter, an increase of \$0.2 million or 31%. Gross profit was negatively affected during the 2007 period as compared to the 2006 period by the incremental increase of \$0.3 million in the write-off or reserve for excess or obsolete inventory, and the decline in product revenues.

The cost of clinical laboratory services during the three month period ended April 30, 2007 was \$5.3 million as compared to \$3.4 million in the year ago period, an increase of \$1.9 million or 55%. Due to the increased volume of patients serviced and tests performed, the Company incurred increased reagent costs of \$0.9 million, payroll related costs of \$0.4 million, and outside testing costs of \$0.5 million.

Research and development expenses were approximately \$2.6 million during the three months ended April 30, 2007, compared to \$1.9 million in the year ago quarter, an increase of \$0.7 million or 38%. The increase was primarily due to

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

an increase at the Therapeutic segment in clinical trial activities of \$0.6 million and an increase in other related costs approximating \$0.1 million.

Selling, general and administrative expenses were comparable in total, at approximately \$6.2 million during both the three months ended April 30, 2007 and 2006. Increases in compensation costs of \$0.5 million were offset by a comparable decline in professional fees and corporate governance costs.

The provision for uncollectible accounts receivable relating to the Clinical Labs segment for the three months ended April 30, 2007 was \$1.3 million as compared to \$0.5 million in the year ago quarter, an increase of \$0.8 million or 159%, and is due to the increase in clinical laboratory revenue and the composition of patients being serviced.

Legal expense was \$3.0 million during the three months ended April 30, 2007 compared to \$1.7 million in the year ago period, an increase of \$1.3 million or 77%, due to an increase in ongoing patent litigation.

19

Interest income increased by \$0.7 million or 85% to \$1.5 million during the three months ended April 30, 2007 compared to \$0.8 million during the 2006 period, due to an increase in invested cash from the sales of common stock in registered direct offerings in December 2006 and February 2007. The net cash proceeds from the offerings were \$57.0 million. See Liquidity and Capital Resources. The Company earns interest by investing primarily in short term (30 to 90 days) commercial paper and money market funds with high credit ratings.

The tax provision for the three months ended April 30, 2007 was based on state and local taxes, and differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency.

The tax benefit for the three months ended April 30, 2006 differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to limitations on the timing of the recognition of the Company's then available federal tax carryback benefit for taxes paid in prior years. The tax benefit also differs from the expected net operating loss carryforward benefit due to the inability to recognize such benefit. The carryforward benefit could not be recognized because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency.

### SEGMENT RESULTS

The Life Sciences segment's income before taxes was approximately \$0.4 million for the three months ended April 30, 2007 as compared to a loss of \$0.2 million in the year ago quarter. Segment revenues increased \$0.5 million to \$2.4 million, with an increase in royalty income of approximately \$0.8 offsetting a decrease in product revenues of \$0.3 million, which resulted from the decline in unit shipments and the continuing competitiveness in the industry. The segment's operations were positively impacted by royalties earned from the License Agreement entered into with Abbott during the fiscal 2007 quarter. Cost of products increased approximately \$0.2 million, due to the write-off or reserve for obsolete inventory, offset by lower shipments. Research and development and selling, general, and administrative declined by approximately \$0.3 million compared to the year ago period.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The Therapeutics segment's loss before taxes was approximately \$1.9 million for the three months ended April 30, 2007 as compared to a loss of \$1.0 million in the year ago quarter. The 2007 period increase in the segment loss was primarily due to an increase in clinical trial activities of \$0.6 million and other related costs of \$0.1 million.

The Clinical Labs segment income before taxes was \$1.4 million for the period ended April 30, 2007 as compared to segment income of \$0.2 million in the year ago quarter. The 2007 period was positively impacted by an increase in service revenues of \$3.8 million, primarily due to the expansion of an insurance provider agreement, which increased gross profit by approximately \$1.9 million. Selling, general and administrative expenses were comparable. The provision for doubtful accounts for the three months ended April 30, 2007 increased by approximately \$0.8 million over the year ago period due to the increase in revenues and the composition of patients being serviced.

The Other segment's loss before income taxes for the three months ended April 30, 2007 was approximately \$3.7 million compared to \$2.8 million in the year ago quarter. The increased segment loss reflects an increase in general, administrative and legal expenses of \$1.4 million due to an increase in ongoing patent litigation and payroll costs, offset by decreases in corporate governance costs and professional fees. The increased expenses were partially offset by an increase in interest income of \$0.7 million.

20

### RESULTS OF OPERATIONS

NINE MONTHS ENDED APRIL 30, 2007 AS COMPARED TO APRIL 30, 2006

#### COMPARATIVE OPERATING DATA

| (in 000's)                             | Nine months ended<br>April 30, |              | Increase<br>(Decrease) |  |
|--|--------------------------------|--------------|------------------------|--|
| REVENUES:                              | 2007<br>----                   | 2006<br>---- | -----                  |  |
| Product revenues                       | \$2,699                        | \$3,900      | \$ (1,201)             |  |
| Royalty income                         | 3,756                          | 2,251        | 1,505                  |  |
| Clinical laboratory services           | 28,543                         | 23,759       | 4,784                  |  |
|  | -----                          | -----        | -----                  |  |
| Total revenues                         | 34,998                         | 29,910       | 5,088                  |  |
| COSTS AND EXPENSES AND OTHER (INCOME): |                                |              |                        |  |
| Cost of products                       | 1,698                          | 1,515        | 183                    |  |
| Cost of laboratory services            | 12,815                         | 10,296       | 2,519                  |  |
| Research & development                 | 6,935                          | 5,361        | 1,574                  |  |
| Selling, general and administrative    | 19,015                         | 18,935       | 80                     |  |
| Provision for uncollectible A/R        | 3,433                          | 2,870        | 563                    |  |
| Legal expenses                         | 7,159                          | 5,213        | 1,946                  |  |
| Interest income                        | (3,627)                        | (2,226)      | (1,401)                |  |
| Other income                           | (2,699)                        | -            | (2,699)                |  |
|  | -----                          | -----        | -----                  |  |
| Total costs and expenses - net         | 44,729                         | 41,964       | 2,765                  |  |
|  | -----                          | -----        | -----                  |  |
| Loss before income taxes               | (\$9,731)                      | (\$12,054)   | \$2,323                |  |

=====

=====

=====

## CONSOLIDATED RESULTS

Product revenues during the nine months ended April 30, 2007 was \$2.7 million compared to \$3.9 million in the year ago quarter, a decrease of \$1.2 million or 31%, due to a decline in unit shipments and the continuing competitiveness in the industry.

Royalty income during the nine months ended April 30, 2007 was \$3.8 million compared to \$2.3 million in the year ago quarter, an increase of \$1.5 million or 67%. Royalties are earned from net sales of Digene products subject to a license and from a License Agreement with Abbott which was entered into in the fiscal 2007 third quarter. There are no expenses relating to royalty income.

Clinical laboratory revenues during the nine month period ended April 30, 2007 were \$28.6 million compared to \$23.8 million in the 2006 period, an increase of \$4.8 million or 20%. The Company experienced an increase in service revenues during the 2007 period due to an expansion of an insurance provider agreement, partially offset by an increase in the contractual adjustment expense which reduced gross billings by 78.4% as compared to 75.0% in the prior period. The increase in the contractual adjustment expense is due to continued competitive pricing throughout the industry.

The cost of products during the nine month periods ended April 30, 2007 was \$1.7 million compared to \$1.5 million in the 2006 period. Gross profit was negatively affected during the 2007 period as compared to the 2006 period by the incremental increase of \$0.1 million in the write-off or reserve for excess or obsolete inventory and the decline in product revenues.

21

The cost of clinical laboratory services during the nine month period ended April 30, 2007 was \$12.8 million as compared to \$10.3 million in the prior period, an increase of \$2.5 million or 24%. Due to the increased volume of patients serviced and tests performed, the Company incurred increased reagent costs of \$1.3 million, payroll related costs of \$0.6 million, and outside testing costs of \$0.5 million.

Research and development expenses were approximately \$6.9 million during the nine months ended April 30, 2007, compared to \$5.3 million in the 2006 period, an increase of \$1.6 million or 29%. The increase was primarily due to increases at the Therapeutic segment in clinical trial activities of \$1.1 million and an increase in other related costs approximating \$0.2 million.

Selling, general and administrative expenses were approximately comparable, at \$19.0 million during the nine months ended April 30, 2007 as compared to \$18.9 million in the 2006 period. Increases in payroll and payroll related personnel costs of \$0.6 million and information technology costs of \$0.1 million were offset primarily by declines in corporate governance and professional fees of \$0.8 million, advertising and promotion expenses of \$0.1 million and insurance of \$0.1 million.

The provision for uncollectible accounts receivable relating to the Clinical Labs segment for the nine months ended April 30, 2007 was \$3.4 million, compared to \$2.9 million during the year ago period, a increase of \$0.5 million or 20% and is due to the increase in clinical laboratory revenue of 20% and the composition of patients being serviced.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

Legal expense was \$7.1 million during the nine months ended April 30, 2007 compared to \$5.2 million in the year ago period, an increase of \$1.9 million or 37%, due to an increase in ongoing patent litigation.

Other income was \$2.7 million during the nine months ended April 30, 2007 versus \$0 in the year ago period. During the 2007 period, the Company as plaintiff and Sigma Aldrich ("Sigma") entered into a Settlement Agreement and Release effective September 15, 2006 (the "Settlement Agreement"). Pursuant to the Settlement Agreement, the Company's litigation with Sigma was dismissed and the Company recognized a \$2 million gain on patent litigation settlement during the nine months ended April 30, 2007. In addition, during the 2007 period, the Company received a payment of \$0.7 million from Perkin Elmer for amounts due under a Distribution Agreement which terminated December 31, 2004. The Distribution Agreement is presently subject to a lawsuit for breach of contract, patent infringement, unfair competition under state law, unfair competition under federal law, tortious interference with business relations, and fraud in the inducement of contract. Perkin Elmer advised in a letter to the Company that the payment under the Distribution Agreement was delayed because of changes to their accounting system and personnel changes and that it was always their intent to comply with the Distribution Agreement. The Company advised Perkin Elmer that the payment did not represent all amounts owed under the Distribution Agreement.

Interest income increased by \$1.4 million or 63% to \$3.6 million during the nine months ended April 30, 2007 compared to \$2.2 million during the 2006 period, due to an increase in invested cash from the sales of common stock in registered direct offerings in December 2006 and February 2007. The net cash proceeds from the offerings were \$57.0 million. See Liquidity and Capital Resources. The Company earns interest by investing primarily in short term (30 to 90 days) commercial paper and money market funds with high credit ratings.

The tax provision for the nine months ended April 30, 2007 was based on state and local taxes, and differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency.

22

The tax benefit for the nine months ended April 30, 2006 differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to limitations on the timing of the recognition of the Company's then available federal tax carryback benefit for taxes paid in prior years. The tax benefit also differed from the expected net operating loss carryforward benefit due to the inability to recognize such benefit. The carryforward benefit could not be recognized because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency. Also due to the uncertainties, the Company recorded during the first quarter of the 2006 period a valuation allowance equal to its net deferred tax assets, including the federal net operating loss carryforward benefit generated during the first quarter of the 2006 period. The Company recorded the valuation allowance as it concluded that it was not more likely than not that its net deferred tax assets would be realized in the foreseeable future based on positive and negative evidence available at the time.

SEGMENT RESULTS



## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The Life Sciences segment's income before taxes was approximately \$3.5 million for the nine months ended April 30, 2007 as compared to \$0.3 million in the 2006 period. The increase is primarily the result of the Company's \$2.0 million patent litigation settlement with Sigma Aldrich, and a payment of \$0.7 million from Perkin Elmer for amounts due under a Distribution Agreement which terminated December 31, 2004. An increase in royalty income of \$1.5 million from the Digene agreement and the Abbott license agreement entered into in the fiscal 2007 third quarter offset a decrease in revenues from product shipments of \$1.2 million due to a decline in unit shipments and the continuing competitiveness in the industry. Segment operating expenses, such as research and development and selling, general and administrative, decreased by approximately \$0.4 million during the 2007 period due to lower payroll and marketing expenses.

The Therapeutics segment's loss before income taxes was approximately \$4.5 million for the nine months ended April 30, 2007 as compared to a loss of \$2.7 million for the 2006 period. The increase in the loss of \$1.8 million was primarily due to increases in clinical trial activities of \$1.1 million and other related costs of \$0.4 million.

The Clinical Labs segment's income before taxes was \$1.6 million for the nine months ended April 30, 2007 as compared to a loss of \$0.1 million in the 2006 period. The 2007 period was positively impacted by an increase in service revenues of \$4.8 million or 20% due to the expansion of an insurance provider agreement, which increased gross profit by approximately \$2.3 million. The increase in gross margin was offset by an increase in the provision for uncollectible accounts for the nine months ended April 30, 2007 of approximately \$0.6 million over the year ago period.

The Other segment's loss before taxes for the nine months ended April 30, 2007 was approximately \$10.4 million as compared to a loss of \$9.6 million in the 2006 period. The increased segment loss reflects an increase in general, administrative and legal expenses of \$2.3 million due to an increase in payroll and personnel related costs of \$1.0 million partially offset by decreases in professional fees and corporate governance expenses of \$0.8 million and insurance of \$0.1 million and an increase in legal costs of \$1.9 million due to ongoing patent litigation. The increase in general, administrative and legal expenses was partially offset by an increase in interest income of \$1.4 million.

23

### LIQUIDITY AND CAPITAL RESOURCES

On December 14, 2006, the Company entered into a Placement Agent Agreement with Lazard Capital Markets LLC, as exclusive placement agent, relating to a "registered direct" offering ("Offering") of shares of the Company's common stock. On December 15, 2006, the Company entered into a definitive Subscription Agreement with various institutional investors relating to the sale of an aggregate of 3,285,715 shares of common stock for a purchase price of \$14.00 per share. Net proceeds from the Offering aggregating \$42.9 million, net of placement fees and financing costs of \$3.1 million, were credited to common stock and additional paid-in capital. On December 15, 2006, the Company filed a prospectus supplement with the SEC relating to the Offering under a shelf Registration Statement on Form S-3 which was effective December 8, 2006 and supplement thereto.

On February 2, 2007, the Company entered into a Placement Agent Agreement with Lazard Capital Markets LLC, as exclusive placement agent, relating to a "registered direct" offering ("Subsequent Offering") of shares of the Company's common stock. On February 2, 2007, the Company entered into a definitive

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

Subscription Agreement with an investor relating to the sale of an aggregate of 1,000,000 shares of common stock for a purchase price of \$15.00 per share. Net proceeds from the Subsequent Offering aggregated \$14.1 million, net of placement fees and financing costs of \$0.9 million, were credited to common stock and additional paid in capital. On February 5, 2007, the Company filed a prospectus supplement with the SEC relating to the Subsequent Offering under the Registration Statement and supplement thereto.

At April 30, 2007, our cash and cash equivalents were \$120.0 million, an increase of \$50.2 million from cash and cash equivalents at July 31, 2006. The increase in cash during the nine months ended April 30, 2007 was primarily due to the Offerings' proceeds, a \$2.0 million settlement gain on patent litigation and cash flow impacts discussed below. The Company had working capital of \$129.1 million at April 30, 2007 compared to \$80.2 million at July 31, 2006. The increase in working capital was primarily the result of the Offerings.

Net cash used in operating activities for the nine months ended April 30, 2007 was approximately \$6.0 million as compared to net cash used in operating activities of \$6.9 million in the 2006 period. The decline in net cash used in operating activities of \$0.9 million in the 2007 period as compared to the 2006 period was due to a decrease in net loss of \$1.2 million offset by a decrease in non-cash charges.

Net cash used in investing activities for the nine months ended April 30, 2007 was approximately \$1.2 million as compared to net cash provided by investing activities of \$5.4 million in the year ago period, primarily due to a decline in the sales of marketable securities of approximately \$6.7 million. During the nine months ended April 30, 2006, all investments in marketable securities were sold and the proceeds reinvested in cash equivalents.

Net cash provided by financing activities for the nine months ended April 30, 2007 was \$57.3 million as compared to \$0.4 million in the year ago period. The increase was primarily due to the proceeds from the Offerings of \$57.0 million previously discussed.

24

Effective May 31, 2007 (the "Effective Date"), the Company's wholly owned subsidiary, Enzo Life Sciences, Inc., completed the acquisition of the stock of Axxora Life Sciences, Inc., ("Axxora") a privately owned global manufacturer and marketer of life sciences research products, for approximately \$16.3 million in cash. On the Effective Date, Axxora became a wholly owned subsidiary of Enzo Life Sciences. Axxora had revenues of approximately \$16 million in 2006. Axxora has wholly-owned subsidiaries in the U.S., Switzerland, Germany and the United Kingdom, as well as distributors located in other major markets. At April 30, 2007, the Company has recorded approximately \$732,000 in acquisition costs which are included in "Other assets" in the accompanying balance sheet.

The Company believes that its current cash position is sufficient for its foreseeable liquidity and capital resource needs over the next 12 months, although there can be no assurance that future events will not alter such view.

### CONTRACTUAL OBLIGATIONS

There were no significant changes to the Contractual Obligations disclosed in the Annual Report on Form 10-K for the 2006 fiscal year.

Management is not aware of any material claims, disputes or settled matters concerning third party reimbursement that would have a material effect on our

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

financial statements.

### CRITICAL ACCOUNTING POLICIES

#### GENERAL

The Company's discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.'s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses; these estimates and judgments also affect related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to contractual adjustments, allowance for uncollectible accounts, inventory, intangible assets and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

#### REVENUE RECOGNITION

The Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, "Revenue Recognition" (SAB 104), when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed and determinable, and (iv) collectibility is reasonably assured. The Company evaluates revenue from agreements that have multiple elements to determine whether the components of the arrangement represent separate units of accounting as defined in EITF Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables" (EITF 00-21). To recognize revenue for a delivered item in a multiple element arrangement, EITF 00-21 requires that the delivered items have value to the customer on a stand-alone basis, there is objective and reliable evidence of fair value of the undelivered items, and delivery of any undelivered items is probable and within our control.

25

#### PRODUCT REVENUES

Revenues from product sales are recognized when the products are shipped, the sales price is fixed or determinable and collectibility is reasonably assured.

#### ROYALTIES AND LICENSING REVENUE

Royalty revenues are recorded in the period earned and no related costs exist. Royalties and license fees received in advance of being earned are recorded as deferred revenues.

#### REVENUES - CLINICAL LABORATORY SERVICES

Revenues from the clinical laboratory are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to providers and the expected approved reimbursable settlements from such providers. The following are tables of the clinical laboratory segment's net revenues and percentages by revenue category

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

for the three and nine months ended April 30, 2007 and 2006:

| Net revenues         | Three months ended<br>April 30, 2007 |        | Three months ended<br>April 30, 2006 |        |
|----------------------|--------------------------------------|--------|--------------------------------------|--------|
| REVENUE CATEGORY     | (In 000'S)                           | (In %) | (In 000'S)                           | (In %) |
| Medicare             | \$2,163                              | 19     | \$1,727                              | 22     |
| Third party provider | 6,632                                | 57     | 4,761                                | 62     |
| Patient self-pay     | 1,643                                | 14     | 682                                  | 9      |
| HMO's                | 1,092                                | 10     | 564                                  | 7      |
| Total                | \$11,530                             | 100%   | \$7,734                              | 100%   |

| Net revenues         | Nine months ended<br>April 30, 2007 |        | Nine months ended<br>April 30, 2006 |        |
|----------------------|-------------------------------------|--------|-------------------------------------|--------|
| REVENUE CATEGORY     | (In 000'S)                          | (In %) | (In 000'S)                          | (In %) |
| Medicare             | \$6,125                             | 21     | \$5,530                             | 23     |
| Third party provider | 17,228                              | 60     | 13,326                              | 56     |
| Patient self-pay     | 3,031                               | 11     | 3,411                               | 15     |
| HMO's                | 2,159                               | 8      | 1,492                               | 6      |
| Total                | \$28,543                            | 100%   | \$23,759                            | 100%   |

The Company provides services to certain patients covered by various third-party providers, including the Federal Medicare program. Revenue, net of contractual adjustments, from gross billings under the Federal Medicare program during the three and nine months ended April 30, 2007 and 2006 were approximately 19% and 22%, and 21% and 23%, respectively, of the clinical lab segment's revenue. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing.

Other than the Medicare program, one provider whose programs are included in the "third party provider" and "HMO's" categories represents 22% and 15% of the Clinical Labs segment's revenue for the three and nine months ended April 30, 2007. Other than the Medicare program, no other provider exceeded 10% of the Clinical Labs segment's revenue for the three and nine months ended April 30, 2006.

### CONTRACTUAL ADJUSTMENTS

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The Company's estimate of contractual adjustments is based on significant assumptions and judgments, such as its interpretation of the applicable providers' reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by providers, versus the corresponding gross amount billed to the respective provider. The contractual adjustment is an estimate that reduces gross revenue, based on gross billing rates, to amounts expected to be approved and reimbursed. The Company adjusts the contractual adjustment estimate periodically, based on its evaluation of historical settlement experience with providers, industry reimbursement trends, and other relevant factors.

During the three and nine months ended April 30, 2007 and 2006, the contractual adjustment percentages, determined using average historical reimbursement statistics, were 79.8% and 75.4% and 78.4% and 75.0%, respectively, of gross billings. The Company estimates (by using a sensitivity analysis) that each 1% point change in the contractual adjustment percentage could have resulted in a change in clinical laboratory services revenues of approximately \$1,321,000 for the nine months ended April 30, 2007, and could have resulted in a change in the net accounts receivable of approximately \$392,000 as of April 30, 2007.

### ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.

For the clinical laboratory segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and adjusts the estimate in future accounting periods as necessary. It bases the estimate for the allowance on the evaluation of historical collection experience, the aging profile of accounts receivable, the historical doubtful account write-off percentages, payer mix, and other relevant factors.

The allowance for doubtful accounts includes the balances, after receipt of the approved settlements from third party providers for the insufficient diagnosis information received from the ordering physician, which result in denials of payment, and the uncollectible portion of receivables from patients including deductibles and copayments which are subject to credit risk and patients' ability to pay. During the three and nine months ended April 30, 2007 and 2006, the Company determined an allowance for doubtful accounts less than 210 days and wrote off 100% of accounts receivable (for all payers) over 210 days, as it assumed those accounts are uncollectible. The Company adjusts the historical collection analysis for recoveries, if any, on an ongoing basis.

The Company's ability to collect outstanding receivables from third party providers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection or reimbursement issues in order to assess the impact, if any, on the allowance estimates, which involves judgment.

The Company believes that the collectibility of its receivables is directly linked to the quality of its billing processes, most notably, those related to

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

obtaining the correct information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount.

The following is a table of the Company's net accounts receivable by segment. The Clinical Labs segment's net receivables are detailed by billing category and as a percent to its total net receivables. At April 30, 2007 and July 31, 2006, approximately 84% and 88%, respectively, of the Company's net accounts receivable relates to its clinical laboratory business, which operates in the New York and New Jersey Metropolitan area.

| Net accounts receivable   | As of          |        | As of         |        |
|---------------------------|----------------|--------|---------------|--------|
|                           | April 30, 2007 |        | July 31, 2006 |        |
| Billing category          | (In 000'S)     | (In %) | (In 000'S)    | (In %) |
| Clinical Labs             |                |        |               |        |
| Medicare                  | \$1,668        | 17     | \$1,367       | 15     |
| Third party providers     | 5,626          | 57     | 4,025         | 44     |
| Patient self-pay          | 1,993          | 20     | 3,294         | 36     |
| HMO's                     | 616            | 6      | 475           | 5      |
| Total Clinical Labs       | 9,903          | 100%   | 9,161         | 100%   |
| Total Life Sciences       | 1,876          |        | 1,286         |        |
| Total accounts receivable | \$11,779       |        | \$10,447      |        |

### INCOME TAXES

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

### INVENTORY

The Company values inventory at the lower of cost (first-in, first-out) or market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. On a quarterly basis, we review inventory quantities on hand and analyze the provision for excess and obsolete inventory based on our estimate of sales forecasts based on sales history and anticipated future demand. Our estimate of future product demand may not be accurate and we may understate or overstate the provision for excess and obsolete inventory. Accordingly, unanticipated changes in demand could have a significant impact on the value of our inventory and results of operations. At April 30, 2007 and July 31, 2006 respectively, the reserve for excess and obsolete inventory was

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

\$360,000 and \$238,000.

28

### Recent Accounting Pronouncements

In May 2005, the FASB issued SFAS No. 154, "Accounting Changes and Error Corrections ("SFAS 154"), a replacement of APB Opinion No. 20, Accounting Changes, and FASB Statement No. 3, Reporting Accounting Changes in Interim Financial Statements". SFAS 154 changes the requirements for the accounting for and reporting of a change in accounting principle. Previously, most voluntary changes in accounting principles required recognition via a cumulative effect adjustment within net income for the period of the change. SFAS 154 requires retrospective application to prior periods' financial statements, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change.

SFAS 154 is effective for accounting changes made in fiscal years beginning after December 15, 2005; however, SFAS 154 does not change the transition provisions of any existing accounting pronouncements. The adoption of SFAS 154 did not have a material impact on the Company's financial condition or results of operations.

In June 2006, the FASB issued FASB Interpretation No. 48 ("FIN 48"), "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, Accounting for Income Taxes" ("SFAS 109")", to clarify the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with SFAS 109. This Interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. The Company has not evaluated the impact of FIN 48 on its financial statements at this time.

In September 2006, the SEC released Staff Accounting Bulletin No. 108 "Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements" ("SAB 108"). SAB 108 provides interpretative guidance on how public companies quantify financial statement misstatements. There have been two common approaches used to quantify such errors. Under an income statement approach, the "roll-over" method, the error is quantified as the amount by which the current year income statement is misstated. Alternatively, under a balance sheet approach, the "iron curtain" method, the error is quantified as the cumulative amount by which the current year balance sheet is misstated. In SAB 108, the SEC established an approach that requires quantification of financial statement misstatements based on the effects of the misstatements on each of the company's financial statements and the related financial statement disclosures. This model is commonly referred to as a "dual approach" because it requires quantification of errors under both the roll-over and iron curtain methods. SAB 108 is effective for the Company as of August 1, 2007. The adoption of SAB 108 is not expected to have a material impact on the Company's consolidated financial statements.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". This Statement defines fair value, establishes a framework for measuring fair value and expands disclosure about fair value measurements, and is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company is currently

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

evaluating the effect that the adoption of this Statement will have on its financial statements at this time.

29

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an amendment of FASB Statement No. 115" ("SFAS 159"). This statement permits entities to choose to measure many financial instruments and certain other items as fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS 159 is effective as of the beginning of fiscal years that begin after November 15, 2007. The Company has not evaluated the effect that the adoption of this Statement will have on its financial statements at this time.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company does not have an exposure to market risk from changes in foreign currency exchange rates, commodity price risk or other market risk. We do not engage in any hedging or market risk management tools. The Company does not have interest risk with respect to interest rates on cash and cash equivalents that could impact our results of operations and financial position since the investments are in highly liquid corporate debt instruments with maturities of three months or less. There have been no material changes with respect to market risk previously disclosed in our Annual Report on Form 10-K for our 2006 fiscal year.

### ITEM 4. CONTROLS AND PROCEDURES

#### (a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company's management conducted an evaluation (as required under Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) of the Company's "disclosure controls and procedures" (as such term is defined under the Exchange Act), under the supervision and with the participation of the principal executive officer and the principal financial officer. Based on this evaluation, the principal executive officer and the principal financial officer concluded that the Company's disclosure controls and procedures are effective as of the end of the period covered by this report. Notwithstanding the foregoing, a control system, no matter how well designed and operated can provide only reasonable, not absolute, assurance that it will detect or uncover failures within the Company to disclose material information otherwise required to be set forth in the Company's periodic reports.

#### (b) Changes in Internal Controls over Financial Reporting

There was no change in the Company's internal controls over financial reporting during the Company's most recently completed interim fiscal period that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

30



# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

## PART II - OTHER INFORMATION

### Item 1. LEGAL PROCEEDINGS

There have been no material developments with respect to previously reported legal proceedings except as noted in Note 9. See the annual report on Form 10-K for the fiscal year ended July 31, 2006 filed with the Securities and Exchange Commission for a discussion of the Company's ongoing legal proceedings.

### Item 1A. RISK FACTORS

Risk and uncertainties that, if they were to occur, could materially adversely affect our business or that could cause our actual results to differ materially from the results contemplated by the forward-looking statements contained in this Report and other public statements we make were set forth in the "Item 1A. - Risk Factors" section of our Annual Report on Form 10-K for the year ended July 31, 2006. There have been no material changes from the risk factors disclosed in that Form 10-K other than the additional risk factors stated below.

CHANGES IN PROVIDER MIX, INCLUDING AN INCREASE IN CAPITATED MANAGED-COST HEALTH CARE, OR LOSS OF A SIGNIFICANT THIRD PARTY CONTRACT COULD HAVE AN ADVERSE IMPACT ON THE COMPANY'S NET REVENUES AND PROFITABILITY.

Certain provider companies have adopted national and regional programs which include multiple managed-care reimbursement models. If the Company is unable to participate in these programs or if the Company would lose a significant contract, it could have an adverse impact on the Company's net revenues and profitability.

### Item 6. EXHIBITS

| Exhibit No.<br>----- | Exhibit<br>-----   |
|----------------------|--|
| 31(a)                | Certification of Elazar Rabbani, Ph.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| 31(b)                | Certification of Barry Weiner pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 32(a)                | Certification of Elazar Rabbani, Ph.D. pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32(b)                | Certification of Barry Weiner pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.           |

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ENZO BIOCHEM, INC.

-----  
(Registrant)

Date: June 11, 2007

by: /S/BARRY WEINER

-----

Chief Financial Officer